Apogee Therapeutics, INC 8-K filings

Apogee Therapeutics stockholders overwhelmingly approved the merger agreement with AbbVie, paving the way for the acquisition.

Apogee Therapeutics announced its second quarter 2026 financial results, highlighting positive Phase 2 trial data for zumilokibart and a definitive agreement to be acquired by AbbVie for approximately $10.9 billion.

Apogee Therapeutics shareholders re-elected three directors and ratified the appointment of Ernst & Young LLP as independent auditor.

Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences, providing up to $1.3 billion in non-dilutive capital to advance its lead drug zumilokibart.

Apogee Therapeutics reported positive 16-week induction dose optimization results from its Phase 2 APEX trial for zumilokibart in moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints.

Apogee Therapeutics announced first quarter 2026 financial results, highlighting progress in its lead drug candidate zumilokibart and a strong cash position extending runway into 2029.

Apogee Therapeutics announces the resignation of two board members, Andrew Gottesdiener and Peter Harwin, effective May 11, 2026.

Apogee Therapeutics, Inc. successfully priced a public offering of 5.75 million common shares at $70.00 each, expecting net proceeds of $377.4 million.

Apogee Therapeutics announced positive 52-week maintenance data from its Phase 2 APEX clinical trial for zumilokibart (APG777) in moderate-to-severe atopic dermatitis, demonstrating durable efficacy and a favorable safety profile with infrequent dosing.

Apogee Therapeutics announced its full year 2025 financial results and provided an update on the progress of its clinical pipeline, including key milestones for zumilokibart (APG777) and APG279.

Apogee Therapeutics announced positive interim Phase 1b data for zumilokibart (APG777) in mild-to-moderate asthma, reinforcing its pipeline potential and outlining key 2026 milestones.

Apogee Therapeutics announced its Q3 2025 financial results and positive interim Phase 1 data for APG333, supporting potential 3to 6-month dosing.

Apogee Therapeutics, Inc. announced a public offering raising approximately $323.3 million and provided updated timelines for its key clinical trials, including delays for APG777 data readouts.

Apogee Therapeutics announced positive Phase 2 APEX trial data for APG777 in atopic dermatitis, accelerated APEX Part B readout, and reported second quarter 2025 financial results.

Apogee Therapeutics announced positive 16-week data from Part A of its Phase 2 APEX clinical trial for APG777 in moderate-to-severe atopic dermatitis, demonstrating superior efficacy and a favorable safety profile compared to existing biologics.

Apogee Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 17, 2025, with all proposed directors elected, the independent auditor ratified, and stockholders voting for annual advisory votes on executive compensation.

Apogee Therapeutics reports positive interim Phase 1b results for APG808 in mild-to-moderate asthma, demonstrating rapid and sustained suppression of FeNO, and provides a business update and Q1 2025 financial results.

Apogee Therapeutics has entered into a Master Services Agreement with Samsung Biologics for the manufacturing and supply of APG777, a drug substance for clinical development and potential commercial sale.

Apogee Therapeutics reports positive interim Phase 1 results for APG990, supporting potential for less frequent dosing of APG279, and announces full year 2024 financial results with a strong cash position.

Apogee Therapeutics has announced the dosing of the first patient in Part B of its Phase 2 APEX trial for APG777 in atopic dermatitis, while also reporting that enrollment for Part A exceeded expectations.

Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 clinical trial for APG333, a novel antibody targeting TSLP for respiratory and inflammatory conditions.

Apogee Therapeutics shared positive interim results from its APG808 Phase 1 trial and updated data from its APG777 Phase 1 trial, along with its strategy for combination therapies in inflammatory and immunology diseases.

Apogee Therapeutics announced positive progress across its pipeline, including promising results from its APG777 Phase 1 trial, and reported its third quarter 2024 financial results.

Apogee Therapeutics reports positive results from its Phase 1 trial of APG777, highlighting a long half-life and strong biomarker inhibition, supporting its potential as a best-in-class treatment for atopic dermatitis.

Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 clinical trial for APG990, a novel antibody treatment for atopic dermatitis.

Apogee Therapeutics announced its second quarter 2024 financial results, highlighted by pipeline advancements and a strong cash position extending into 2028.

Apogee Therapeutics held its 2024 Annual Meeting of Stockholders, electing three Class I directors and ratifying Ernst & Young LLP as its independent auditor.

Apogee Therapeutics has appointed Lisa Bollinger, MD, a seasoned pharmaceutical executive with extensive regulatory experience, to its board of directors.

Apogee Therapeutics has begun dosing patients in a Phase 2 clinical trial for APG777, a novel antibody treatment for moderate-to-severe atopic dermatitis.

Apogee Therapeutics announced its first quarter 2024 financial results, highlighted by pipeline advancements and a strong cash position.